

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/886,779	06/21/2001	Chandran R. Sabanayagam	701586/50113-C	6933
26248 75	590 02/13/2002			
NIXON PEABODY LLP			EXAMINER	
101 FEDERAL ST BOSTON, MA 02110			LU, FRANK WEI MIN	
			ART UNIT	PAPER NUMBER
			1634	<u> </u>
			DATE MAILED: 02/13/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

		}.
	Application No.	Applicant(s)
	09/886,779	SABANAYAGAM ET AL.
Office Action Summary	Examiner	Art Unit
	Frank W Lu	1655
	ation appears on the cover sl	neet with the correspondence address
Period for Reply		OF 2 MONTH(C) EDOM
A SHORTENED STATUTORY PERIOD FO THE MAILING DATE OF THIS COMMUNIC - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commun - If the period for reply specified above is less than thirty (30) - If NO period for reply is specified above, the maximum statu - Failure to reply within the set or extended period for reply wi - Any reply received by the Office later than three months afte earned patent term adjustment. See 37 CFR 1.704(b). Status	ATION. 37 CFR 1.136(a). In no event, however nication. days, a reply within the statutory minimutory period will apply and will expire SIX III, by statute, cause the application to be	may a reply be timely filed from of thirty (30) days will be considered timely. (6) MONTHS from the mailing date of this communication. come ABANDONED (35 U.S.C. § 133).
1) Responsive to communication(s) file	d on <i>21 June 2001</i> .	
,	o)⊠ This action is non-fina	· •
· —	, ——	nal matters, prosecution as to the merits is
closed in accordance with the practic		
Disposition of Claims		
4) Claim(s) 11 and 23 is/are pending in	the application.	
4a) Of the above claim(s) is/are	withdrawn from consideration	on.
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>11 and 23</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restricti	on and/or election requireme	ent.
Application Papers		
9) The specification is objected to by the	Examiner.	
10) The drawing(s) filed on is/are: a	a) accepted or b) objected	to by the Examiner.
Applicant may not request that any object	ction to the drawing(s) be held i	n abeyance. See 37 CFR 1.85(a).
11)☐ The proposed drawing correction filed	on is: a)☐ approved	b) disapproved by the Examiner.
If approved, corrected drawings are requ	ired in reply to this Office action	n.
12) The oath or declaration is objected to be	by the Examiner.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim f	or foreign priority under 35 L	J.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
 Certified copies of the priority d 	ocuments have been receive	ed.
2. Certified copies of the priority d	ocuments have been receive	ed in Application No
	itional Bureau (PCT Rule 17	
14)⊠ Acknowledgment is made of a claim for		
a) The translation of the foreign lang	juage provisional application	n has been received.
15)⊠ Acknowledgment is made of a claim fo	r domestic priority under 35	U.S.C. §§ 120 and/or 121.
Attachment(s)		
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PT 3) Information Disclosure Statement(s) (PTO-1449) Page 1 	O-948) 5) 🔲 N	nterview Summary (PTO-413) Paper No(s) lotice of Informal Patent Application (PTO-152) ther:

Application/Control Number: 09/886,779

Art Unit: 1634

DETAILED ACTION

Location of Application

1. The Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1634.

Sequence Rules Compliance

2. This application has complied with Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.
- 4. Claims 11 and 23 are rejected under 35 U.S.C. 102(b) as being anticipated by Caviani Pease *et al.*, (Proc. Natl. Acad. Sci. USA, 91, 5022-5026, 1994).

Art Unit: 1634

Caviani Pease *et al.*, teach a light-generated oligonucleotide array. For example, see abstract in page 5022 and Figure 4 in page 5025. Although Caviani Pease *et al.*, did not show an ordered redundant array of immobilized oligonucleotides produced by the method recited in claims 11 or 23, it was well established that even though product-by process claims are limited by and defined by the process, the determination of the patentability of the product is based on the product itself. The patentability of a product did not depend on its method of production. If the product in the product-by-process claim was the same as or obvious from a product of the prior art, the claim would be unpatentable even though the prior product was made by a different process." *In re Thorpe*, 227 USPO 964, 966 (Fed. Cir. 1985).

Therefore, Caviani Pease et al., teach all limitations recited in claims 11 and 23.

5. Claims 11 and 23 are rejected under 35 U.S.C. 102(e) as being anticipated by Chetverin et al., (US Patent 6,103,463, filed on May 23, 1994).

Chetverin *et al.*, teach ordered arrays of oligonucleotides immobilized on a solid support. For example, see columns 1 and 44, and Figure 1. Although Chetverin *et al.*, did not show an ordered redundant array of immobilized oligonucleotides produced by the method recited in claims 11 or 23, it was well established that even though product-by process claims are limited by and defined by the process, the determination of the patentability of the product is based on the product itself. The patentability of a product did not depend on its method of production. If the product in the product-by-process claim was the same as or obvious from a product of the

Art Unit: 1634

prior art, the claim would be unpatentable even though the prior product was made by a different process." *In re Thorpe*, 227 USPQ 964, 966 (Fed. Cir. 1985).

Therefore, Chetverin et al., teach all limitations recited in claims 11 and 23.

Conclusion

- 6. No claim is allowed.
- 7. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is either (703) 308-4242 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (703) 305-1270. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

Frank Lu February 11, 2002

ETHAN C. WHISENANT PRIMARY EXAMPLE